Overview
Browse spinoutsLegal name
VAXEQUITY LTD.
Region
East of England
Registered address
Unknown
Insolvency history
No
Spinout
Active
LTD
Company profile
Vaxequity LTD.
Home page - VaxEquity
VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines.
CRN
12620906
Founded
2020
Age
5
Corporate ownership
Updated 07 Jul 2026 09:49
3 levels
1 ultimate controller
1
Company
Active
LTD
Vaxequity LTD.
CRN 12620906
2
Direct controller
Active
LTD
Astrazeneca UK Limited
CRN 03674842
3
Intermediate controller
Active
LTD
Astrazeneca Intermediate Holdings Limited
CRN 06442028
4
Ultimate controller
Active
PLC
Astrazeneca PLC
CRN 02723534
Company events
Reference milestones and recent Companies House filing stream events.
1 event
26 May
2020
Incorporated
InceptionCompany registered at Companies House
Spinout profile
1 entry
Company description
VaxEquity was founded in 2020 by Imperial College and Morningside. VaxEquity develops transformative RNA therapeutics and vaccines using its next generation self-amplifying RNA platform.VaxEquity uses saRNA to provide extended duration of protein expression. This enables lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next generation approach by modifying its self-amplifying RNA (saRNA) to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the Company's platform ensures that its broad pipeline of assets can be designed, developed and manufactured rapidly and at scale.
Project impact
AstraZeneca has provideed VaxEquity with £195 million of R&D funding and has invested in the biotech as part of a long-term effort to optimize and validate the saRNA platform. In return, AstraZeneca will gain a chance to work with VaxEquity on up to 26 drug targets.
VAXEQUITY LTD.
2020
Public funding
1 award
First funded
2023
Funded years
2023
Age at first award
3 years
Projects
2023
Collaborative R&D
Lead participant
Quality, yield and cost optimisations of in vitro transcription reactions for saRNA therapeutics
1 Jun 2023 to 31 May 2024
Awarded
£166,166
Total cost £237,380
The potential of nucleic acids as vaccines and therapeutics is only just being realised and the success of the Covid mRNA vaccines is due in part to the rate at which scale-up and manufacture was possible. VaxEquity is a biotechnology company seeking to develop novel, second-generation RNA based vaccines and therapeutics. Working in collaboration with the...
Product types
Collaborative R&D